Ropes & Gray will lead an internal investigation at British pharmaceutical giant GlaxoSmithKline Plc. (GSK), following Chinese government allegations that the company’s China operations paid almost $500 million in bribes to help boost sales.
GSK has admitted that some of Chinese employees may have broken Chinese laws. China's Ministry of Public Security has said it believes GSK paid bribes to doctors and other officials to get them to use its products over those of competitors. Chinese police have detained four Chinese executives from GSK, including the company’s China legal affairs director Zhao Hongyan.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
